Decision Tool Predicts Efficacy of Vedolizumab but Not Ustekinumab in Refractory Crohn's Disease
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Inflammatory Bowel Diseases
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Vedolizumab Clinical Decision Support Tool Predicts Efficacy of Vedolizumab but Not Ustekinumab in Refractory Crohn's Disease
Inflamm. Bowel Dis. 2021 Apr 13;[EPub Ahead of Print], H Alric, A Amiot, J Kirchgesner, X Tréton, M Allez, Y Bouhnik, L Beaugerie, F Carbonnel, A MeyerFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.